Erosive Esophagitis: Developing Drugs for Treatment

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled “Erosive Esophagitis: Developing Drugs for Treatment.” The draft guidance details recommendations on clinical trials for drugs being developed for the healing of

erosive esophagitis (EE) and maintenance of healed EE in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.